Use of Radical Cystectomy for Patients With Invasive Bladder Cancer
Open Access
- 16 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 102 (11), 802-811
- https://doi.org/10.1093/jnci/djq121
Abstract
Evidence-based guidelines recommend radical cystectomy for patients with muscle-invasive bladder cancer. However, many patients receive alternate therapies, such as chemotherapy or radiation. We examined factors that are associated with the use of radical cystectomy for invasive bladder cancer and compared the survival outcomes of patients with invasive bladder cancer by the treatment they received. From linked Surveillance, Epidemiology, and End Results–Medicare data, we identified a cohort of 3262 Medicare beneficiaries aged 66 years or older at diagnosis with stage II muscle-invasive bladder cancer from January 1, 1992, through December 31, 2002. We examined the use of radical cystectomy with multilevel multivariable models and survival after diagnosis with the use of instrumental variable analyses. All statistical tests were two-sided. A total of 21% of the study subjects underwent radical cystectomy. Older age at diagnosis and higher comorbidity were associated with decreased odds of receiving cystectomy (for those ≥80 vs 66–69 years old, odds ratio [OR] = 0.10, 95% confidence interval [CI] = 0.07 to 0.14; for Charlson comorbidity index of 3 vs 0–1, OR = 0.25, 95% CI = 0.14 to 0.45). Long travel distance to an available surgeon was associated with decreased odds of receiving cystectomy (for >50 vs 0–4 miles travel distance to an available surgeon, OR = 0.60, 95% CI = 0.37 to 0.98). Overall survival was better for those who underwent cystectomy compared with those who underwent alternative treatments (for chemotherapy and/or radiation vs cystectomy, hazard ratio of death = 1.5, 95% CI = 1.3 to 1.8; for surveillance vs cystectomy, hazard ratio of death = 1.9, 95% CI = 1.6 to 2.3; 5-year adjusted survival: 42.2% [95% CI = 39.1% to 45.4%] for cystectomy; 20.7% [95% CI = 18.7% to 22.8%] for chemotherapy and/or radiation; 14.5% [95% CI = 13.0% to 16.2%] for surveillance). Guideline-recommended care with radical cystectomy is underused for patients with muscle-invasive bladder cancer. Many bladder cancer patients whose survival outcomes might benefit with surgery are receiving alternative less salubrious treatments.Keywords
This publication has 43 references indexed in Scilit:
- Access to Cancer Services for Rural Colorectal Cancer PatientsThe Journal of Rural Health, 2008
- Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modelingJournal of Health Economics, 2008
- Diffusion of surgical innovation among patients with kidney cancerCancer, 2008
- Health Care Utilization and the Proportion of Primary Care PhysiciansAmerican Journal Of Medicine, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Volume, Process of Care, and Operative Mortality for Cystectomy for Bladder CancerUrology, 2007
- Analysis of Observational Studies in the Presence of Treatment Selection BiasJama-Journal Of The American Medical Association, 2007
- Factors Influencing Aggressive Therapy for Bladder Cancer: An Analysis of Data From the SEER ProgramJournal of Urology, 2003
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987